Methylphenidate in ADHD With Trichotillomania
Methylphenidate Treatment of Children and Adolescents Diagnosed With ADHD and Its Influence on Comorbid Trichotillomania
2 other identifiers
interventional
30
1 country
1
Brief Summary
This study will evaluate the safety and effectiveness of methylphenidate in treating attention deficit hyperactivity disorder (ADHD) in children with both ADHD and trichotillomania. Trichotillomania is an impulse control disorder. There is growing evidences of the involvement of dopaminergic neurotransmission in the pathophysiology of trichotillomania. Reported increase in the prevalence of ADHD among patients with impulse control disorders, such as pathological gambling as well as trichotillomania, may result from the overlapping pathophisiological background. It is hypothesized that in cases of ADHD comorbid with trichotillomania methtylphenidate treatment will exhibit beneficial effects in both the ADHD and the hair pulling.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_4
Started Oct 2007
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2007
CompletedFirst Submitted
Initial submission to the registry
October 31, 2007
CompletedFirst Posted
Study publicly available on registry
November 1, 2007
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2009
CompletedNovember 1, 2007
October 1, 2007
October 31, 2007
October 31, 2007
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Clinicial administered Massachusetts General Hospital Hair Pulling Scale for trichotillomania
First 6 weeks of treatment
Secondary Outcomes (1)
Clinicial administered ADHD Rating Scale Clinical Global Impressions (CGI) scale for ADHD severity Weekly spontaneous self report of side effects
Within the first 6 weeks of treatment
Interventions
tablets 10-60 mg/day administered once or twice daily 6 weeks
Eligibility Criteria
You may qualify if:
- DSM-IV Diagnosis of trichotillomania
- DSM-IV diagnosis of ADHD
- Has not taken stimulants or alpha-adrenergic medications for more than 2 weeks prior to entering the study.
You may not qualify if:
- History of moderate or severe adverse event, related to MPH
- History of any psychotic disorder
- Current drug abuse, acute psychotic or affective disorder
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Geha Mental Health Centerlead
- Clalit Health Servicescollaborator
Study Sites (1)
Geha Mental Health Center
Petah Tikva, 49100, Israel
Related Publications (1)
Golubchik P, Sever J, Weizman A, Zalsman G. Methylphenidate treatment in pediatric patients with attention-deficit/hyperactivity disorder and comorbid trichotillomania: a preliminary report. Clin Neuropharmacol. 2011 May-Jun;34(3):108-10. doi: 10.1097/WNF.0b013e31821f4da9.
PMID: 21586916DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Pavel Golubchik, M.D.
Geha Mental Health Center
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
October 31, 2007
First Posted
November 1, 2007
Study Start
October 1, 2007
Study Completion
October 1, 2009
Last Updated
November 1, 2007
Record last verified: 2007-10